OncoMatch/Clinical Trials/Testicular / Germ Cell Cancer
Testicular / Germ Cell Cancer Clinical Trials
OncoMatch filters Testicular / Germ Cell Cancer trials by the molecular markers that determine eligibility — KIT, KRAS, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaAbout Testicular / Germ Cell Cancer trials
Testicular cancer (germ cell tumors / GCT) is one of the most curable solid cancers, with stage I-II 5-year survival above 95%. KIT alterations occur in a subset of seminomas and may appear in molecularly selected exploratory trials, but tumor markers and IGCCCG risk classification drive eligibility far more often than sequencing results. KRAS mutations are less common and primarily relevant in non-seminoma cohorts. Tumor markers (AFP, β-hCG, LDH) are central to GCT clinical management and drive IGCCCG risk classification more than mutation status in most cases. These markers are tracked in blood rather than via tumor sequencing.
Testicular cancer trial activity centers on stage, IGCCCG risk classification, and prior chemotherapy. Front-line trials test variations on the BEP regimen (bleomycin, etoposide, cisplatin), de-escalation strategies for early-stage disease (single-cycle adjuvant carboplatin for stage I seminoma vs surveillance), and intensification for poor-risk patients. Salvage trials test TIP (paclitaxel, ifosfamide, cisplatin) and high-dose chemotherapy with autologous stem cell transplant for platinum-refractory or relapsed disease. Mediastinal germ cell tumor trials are typically separate because of worse prognosis. Late-effects and survivorship trials are an active area given the high cure rates and long survival in this young patient population, focused on reducing cardiovascular toxicity (post-bleomycin and post-cisplatin), second malignancy risk, and fertility preservation.
Testicular cancer trial intake usually checks histology, IGCCCG risk classification, and prior chemotherapy. Histology (seminoma vs non-seminoma vs mixed) gates which trial set applies. IGCCCG risk classification (good, intermediate, poor) by tumor markers, primary site, and metastatic distribution determines trial eligibility for risk-stratified studies. Prior BEP / EP exposure for line-specific trials. Prior salvage chemotherapy (TIP) and prior high-dose chemotherapy + autoSCT for refractory trials. Pulmonary function status, particularly post-bleomycin (DLCO), gates trials testing further bleomycin or pulmonary-toxic agents. Performance status, with most trials accepting ECOG 0-1. Fertility preservation considerations, where many trials include sperm banking discussions and accept patients who have completed banking.
Top recruiting Testicular / Germ Cell Cancer trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Children's Oncology Group
Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.
Indiana University
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
University of Sydney
Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors
Gustave Roussy, Cancer Campus, Grand Paris
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Children's Oncology Group
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
Wake Forest University Health Sciences
How OncoMatch finds Testicular / Germ Cell Cancer trials for you
AI reads the protocol
Every Testicular / Germ Cell Cancer trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Testicular / Germ Cell Cancer and mark your biomarker results — KIT, KRAS — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.